Notice2023-04697
Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)-RFA-PS23-001, Increasing PrEP Use Among Disproportionately Affected Populations in the United States and RFA-PS23-003, Exploring Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a Community-Based Sample of Priority Populations Living With HIV Who Are Disproportionately Affected; Amended Notice of Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 8, 2023
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 45 (Wednesday, March 8, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 45 (Wednesday, March 8, 2023)]
[Notices]
[Pages 14372-14373]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-04697]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP)--RFA-PS23-001, Increasing PrEP Use Among
Disproportionately Affected Populations in the United States and RFA-
PS23-003, Exploring Preferences for Long-Acting Antiretroviral
Therapies (LA-ART) in a Community-Based Sample of Priority Populations
Living With HIV Who Are Disproportionately Affected; Amended Notice of
Meeting
Notice is hereby given of a change in the meeting of the Disease,
Disability, and Injury Prevention and Control Special Emphasis Panel
(SEP)--RFA-PS23-001, Increasing PrEP Use Among Disproportionately
Affected Populations in the United States and RFA-PS23-003, Exploring
Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a
Community-Based Sample of Priority Populations Living with HIV Who are
Disproportionately Affected, May 11-12, 2023, 10 a.m.-5 p.m., EDT,
Teleconference, Centers for Disease Control and Prevention, Room 1077,
8 Corporate Blvd., Atlanta, GA 30329, in the original FRN. The meeting
was published in the Federal Register on February 13, 2023, Volume 88,
Number 29, page/s/ 9288-9289.
The meeting is being amended to change the title of RFA-PS23-001,
Increasing PrEP Use Among Disproportionately Affected Populations in
the United States to RFA-PS23-001, Increasing PrEP Use Among Black
Cisgender Women in the United States (HerPrEP) and to remove RFA-PS23-
003, Exploring Preferences for Long-Acting Antiretroviral Therapies
(LA-ART) in a Community-Based Sample of Priority Populations Living
with HIV Who are Disproportionately Affected and replace with RFA-PS23-
005, Expanding Rapid Initiation of Antiretroviral Therapy in Non-
traditional Settings: Emergency Department. The date of the
teleconference will also change and should read as follows:
Date: May 24-25, 2023.
Place: Teleconference, Centers for Disease Control and Prevention,
Room 1077, 8 Corporate Blvd., Atlanta, GA 30329.
The meeting is closed to the public.
FOR FURTHER INFORMATION CONTACT: Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, National
[[Page 14373]]
Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, 1600
Clifton Road NE, Mailstop US8-1, Atlanta, Georgia 30329, Telephone:
(404) 718-8833, Email: <a href="/cdn-cgi/l/email-protection#2364624d474651504c4d634047400d444c55"><span class="__cf_email__" data-cfemail="b9fef8d7dddccbcad6d7f9daddda97ded6cf">[email protected]</span></a>.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-04697 Filed 3-7-23; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 8, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.